Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)
Close on Nov 17, 2026Market cap $666.15MP/E –Yield –
Fulgent Genetics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Fulgent Genetics's ebitda for the twelve months ending Jun 30, 2026 was -$96.46M. For fiscal 2025 it was -$66.97M. The highest annual figure on record is $686.96M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$66.97M | – |
| FY2024 | Dec 31, 2024 | -$48.99M | – |
| FY2023 | Dec 31, 2023 | -$169.39M | -180.2% |
| FY2022 | Dec 31, 2022 | $211.19M | -69.3% |
| FY2021 | Dec 31, 2021 | $686.96M | +134.4% |
| FY2020 | Dec 31, 2020 | $293.12M | +17358.0% |
| FY2019 | Dec 31, 2019 | $1.68M | – |
| FY2017 | Dec 31, 2017 | -$1.75M | -184.0% |
| FY2016 | Dec 31, 2016 | $2.09M | – |
| FY2015 | Dec 31, 2015 | -$4.44M | – |
| FY2014 | Dec 31, 2014 | -$794.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$28.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$30.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$13.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.88M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.94M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.16M | -268.2% |
| Q2 FY2024 | Jun 30, 2024 | -$12.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$144.59M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.63M | -34.8% |
| Q2 FY2023 | Jun 30, 2023 | -$13.49M | -163.8% |
| Q1 FY2023 | Mar 31, 2023 | -$17.95M | -108.7% |
| Q4 FY2022 | Dec 31, 2022 | -$26.75M | -117.3% |
| Q3 FY2022 | Sep 30, 2022 | $10.17M | -93.7% |
| Q2 FY2022 | Jun 30, 2022 | $21.14M | -79.1% |
| Q1 FY2022 | Mar 31, 2022 | $206.63M | -23.1% |
| Q4 FY2021 | Dec 31, 2021 | $154.35M | -32.0% |
| Q3 FY2021 | Sep 30, 2021 | $162.45M | +152.9% |
| Q2 FY2021 | Jun 30, 2021 | $101.32M | – |
| Q1 FY2021 | Mar 31, 2021 | $268.84M | – |
| Q4 FY2020 | Dec 31, 2020 | $227.03M | – |
| Q3 FY2020 | Sep 30, 2020 | $64.25M | +25094.1% |
| Q1 FY2018 | Mar 31, 2018 | -$1.68M | -365.9% |
| Q4 FY2017 | Dec 31, 2017 | -$1.60M | -195.1% |
| Q3 FY2017 | Sep 30, 2017 | -$1.04M | – |
| Q2 FY2017 | Jun 30, 2017 | $255.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $631.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.68M | – |
| Q3 FY2016 | Sep 30, 2016 | -$391.00K | – |
See a number that looks wrong?